Loading
companiesCompany
TJ Biopharma
TJ Biopharma is a Chinese developer in Shanghai that sponsors 2 registered cancer trials of Uliledlimab and Sintilimab.
Also called: TJ Biopharma Co., Ltd.
Overview
TJ Biopharma appears on ClinicalTrials.gov as the industry sponsor of 2 interventional cancer trials (phase 2, 2/3), testing Uliledlimab, Sintilimab, Pemetrexed, Toripalimab in non small cell lung cancer. OnCo records the company from the registry alone: the head office city comes from its registered name, and there are no website, funding or approval claims until they are sourced.
Similar pages
- TreatmentUliledlimab
Shares A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer, A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untr.
- CompanyBeijing Gene Key Life Technology
Shares the tags china, registry-only.
- CompanyBeijing Konruns Pharmaceutical
Shares the tags china, registry-only.
- CompanyBeijing Mabworks Biotech
Shares the tags china, registry-only.
- CompanyBeijing Pearl Biotechnology Limited Liability Company
Shares the tags china, registry-only.
- CompanyBeijing Scitech-Mq Pharmaceuticals
Shares the tags china, registry-only.
- CompanyBeijing Tide Pharmaceutical
Shares the tags china, registry-only.
- CompanyBinhui Biopharmaceutical
Shares the tags china, registry-only.
trials
A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously UntrA Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer